Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier.
Despite significant advances in highly active antiretroviral therapy (HAART), the prevalence of neuroAIDS remains high. This is mainly attributed to inability of antiretroviral therapy (ART) to cross the blood-brain barrier (BBB), thus resulting in insufficient drug concentration within the brain. Therefore, development of an active drug targeting system is an attractive strategy to increase the efficacy and delivery of ART to the brain. We report herein development of magnetic azidothymidine 5'-triphosphate (AZTTP) liposomal nanoformulation and its ability to transmigrate across an in vitro BBB model by application of an external magnetic field. We hypothesize that this magnetically guided nanoformulation can transverse the BBB by direct transport or via monocyte-mediated transport. Magnetic AZTTP liposomes were prepared using a mixture of phosphatidyl choline and cholesterol. The average size of prepared liposomes was about 150 nm with maximum drug and magnetite loading efficiency of 54.5% and 45.3%, respectively. Further, magnetic AZTTP liposomes were checked for transmigration across an in vitro BBB model using direct or monocyte-mediated transport by application of an external magnetic field. The results show that apparent permeability of magnetic AZTTP liposomes was 3-fold higher than free AZTTP. Also, the magnetic AZTTP liposomes were efficiently taken up by monocytes and these magnetic monocytes showed enhanced transendothelial migration compared to normal/non-magnetic monocytes in presence of an external magnetic field. Thus, we anticipate that the developed magnetic nanoformulation can be used for targeting active nucleotide analog reverse transcriptase inhibitors to the brain by application of an external magnetic force and thereby eliminate the brain HIV reservoir and help to treat neuroAIDS.
Saiyed
Zainulabedin M
ZM
Department of Immunology, College of Medicine, Florida International University, Miami, FL, USA.
Gandhi
Nimisha H
NH
Nair
Madhavan P N
MP
D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry; D001812:Blood-Brain Barrier / Q000737:chemistry*; D002478:Cells, Cultured; D054306:Dideoxynucleotides / Q000008:administration & dosage* / Q000737:chemistry*; D004058:Diffusion; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods; D004574:Electromagnetic Fields; D006801:Humans; D008422:Materials Testing; D050997:Nanomedicine / Q000379:methods; D049329:Nanostructures / Q000008:administration & dosage / Q000737:chemistry*; D013942:Thymine Nucleotides / Q000008:administration & dosage* / Q000737:chemistry*; D015215:Zidovudine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry
D000998:Antiviral Agents; D054306:Dideoxynucleotides; D004337:Drug Carriers; D013942:Thymine Nucleotides; D015215:Zidovudine; C052873:zidovudine triphosphate
Mol Med Today. 1997 Aug;3(8):335-41
9269686
Radiology. 2007 Aug;244(2):439-48
17562813
Int J Oncol. 2000 Aug;17(2):309-15
10891540
J Immunol. 2009 Jul 1;183(1):661-9
19535632
J Transl Med. 2009 Sep 01;7:77
19723323
J Control Release. 2008 Dec 8;132(2):84-90
18805446
Bioconjug Chem. 2007 Sep-Oct;18(5):1498-506
17760417
Surg Neurol. 2007 Feb;67(2):113-6
17254859
AIDS Res Hum Retroviruses. 1990 May;6(5):691-702
2163269
Nature. 1990 Jan 4;343(6253):85-9
2296295
Expert Opin Drug Deliv. 2007 Jan;4(1):5-17
17184158
Nat Rev Drug Discov. 2004 Jun;3(6):499-508
15173839
Anal Biochem. 1980 May 1;104(1):10-4
6892980
Nanomedicine (Lond). 2009 Jul;4(5):557-74
19572821
Blood. 2006 Oct 15;108(8):2827-35
16809617
J Leukoc Biol. 2005 Dec;78(6):1223-32
16204625
Blood. 1992 Mar 1;79(5):1137-43
1371411
Mol Pharm. 2005 Nov-Dec;2(6):449-61
16323952
AIDS Res Hum Retroviruses. 1994 Sep;10(9):1179-86
7826702
Biomaterials. 2008 Feb;29(4):487-96
17964647
Eur J Neurosci. 2003 Nov;18(9):2538-44
14622154
J Chromatogr. 1992 Aug 7;579(1):107-14
1447336
J Neuroimmune Pharmacol. 2007 Mar;2(1):105-11
18040833
AIDS Res Hum Retroviruses. 2009 Jul;25(7):691-9
19621989
Med Sci (Paris). 2004 Oct;20(10):882-6
15461965
J Biosci Bioeng. 2005 Jul;100(1):1-11
16233845
AIDS. 2008 Aug 20;22(13):1539-49
18670212
J Immunol. 1997 Apr 1;158(7):3499-510
9120312
J Control Release. 2007 Aug 16;121(1-2):19-27
17509713
J Occup Med Toxicol. 2007 Dec 01;2:16
18053152
Int J Pharm. 2003 Aug 11;261(1-2):43-55
12878394
Gene Ther. 2008 Jun;15(12):902-10
18418420
N Engl J Med. 1995 Apr 6;332(14):934-40
7877652
Biomagn Res Technol. 2003 Sep 18;1(1):2
14521720
Annu Rev Microbiol. 1992;46:655-93
1444270
AIDS Res Hum Retroviruses. 1996 Feb 10;12(3):223-8
8835200
J Neurovirol. 2009 Jul;15(4):343-7
19575326
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):23-30
16340469